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Abstract: Acetaminophen (APAP) overdoses are of major clinical concern. Growing evidence under-
lines a pathogenic contribution of sterile postinjury inflammation in APAP-induced acute liver injury
(APAP-ALI) and justifies development of anti-inflammatory therapies with therapeutic efficacy beyond
the therapeutic window of the only current treatment option, N-acetylcysteine (NAC). The inflammatory
mediator, high mobility group box 1 (HMGB1), is a key regulator of a range of liver injury conditions and
is elevated in clinical and preclinical APAP-ALI. The anti-HMGB1 antibody (m2G7) is therapeutically
beneficial in multiple inflammatory conditions, and anti-HMGB1 polyclonal antibody treatment improves
survival in a model of APAP-ALI. Herein, we developed and investigated the therapeutic efficacy of a
partly humanized anti-HMGB1 monoclonal antibody (mAb; h2G7) and identified its mechanism of action
in preclinical APAP-ALI. The mouse anti-HMGB1 mAb (m2G7) was partly humanized (h2G7) by merg-
ing variable domains of m2G7 with human antibody-Fc backbones. Effector function-deficient variants
of h2G7 were assessed in comparison with h2G7 in vitro and in preclinical APAP-ALI. h2G7 retained
identical antigen specificity and comparable affinity as m2G7. 2G7 treatments significantly attenuated
APAP-induced serum elevations of alanine aminotransferase and microRNA-122 and completely abro-
gated markers of APAP-induced inflammation (tumor necrosis factor, monocyte chemoattractant protein
1, and chemokine [C-X-C motif] ligand 1) with prolonged therapeutic efficacy as compared to NAC.
Removal of complement and/or Fc receptor binding did not affect h2G7 efficacy. Conclusion: This is the
first report describing the generation of a partly humanized HMGB1-neutralizing antibody with validated
therapeutic efficacy and with a prolonged therapeutic window, as compared to NAC, in APAP-ALI. The
therapeutic effect was mediated by HMGB1 neutralization and attenuation of postinjury inflammation.
These results represent important progress toward clinical implementation of HMGB1-specific therapy
as a means to treat APAP-ALI and other inflammatory conditions. (Hepatology 2016;64:1699-1710).
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A Novel High Mobility Group Box 1
Neutralizing Chimeric Antibody
Attenuates Drug-Induced Liver Injury
and Postinjury Inflammation in Mice
Peter Lundb€ack,1 Jonathan D. Lea,2 Agnieszka Sowinska,1 Lars Ottosson,3 Camilla Melin F€urst,4 Johanna Steen,1 Cecilia Aulin,1
Joanna I. Clarke,2 Anja Kipar,2 Lena Klevenvall,3 Huan Yang,5 Karin Palmblad,3 B. Kevin Park,2 Kevin J. Tracey,5
Anna M. Blom,4 Ulf Andersson,3 Daniel J. Antoine,2* and Helena Erlandsson Harris1*
Acetaminophen (APAP) overdoses are of major clinical concern. Growing evidence underlines a pathogenic contribution of sterile
postinjury inﬂammation in APAP-induced acute liver injury (APAP-ALI) and justiﬁes development of anti-inﬂammatory thera-
pies with therapeutic efﬁcacy beyond the therapeutic window of the only current treatment option, N-acetylcysteine (NAC). The
inﬂammatory mediator, high mobility group box 1 (HMGB1), is a key regulator of a range of liver injury conditions and is elevated
in clinical and preclinical APAP-ALI. The anti-HMGB1 antibody (m2G7) is therapeutically beneﬁcial in multiple inﬂammatory
conditions, and anti-HMGB1 polyclonal antibody treatment improves survival in a model of APAP-ALI. Herein, we developed
and investigated the therapeutic efﬁcacy of a partly humanized anti-HMGB1 monoclonal antibody (mAb; h2G7) and identiﬁed its
mechanism of action in preclinical APAP-ALI. The mouse anti-HMGB1 mAb (m2G7) was partly humanized (h2G7) by merg-
ing variable domains of m2G7 with human antibody-Fc backbones. Effector function-deﬁcient variants of h2G7 were assessed in
comparison with h2G7 in vitro and in preclinical APAP-ALI. h2G7 retained identical antigen speciﬁcity and comparable afﬁnity
as m2G7. 2G7 treatments signiﬁcantly attenuated APAP-induced serum elevations of alanine aminotransferase and microRNA-
122 and completely abrogated markers of APAP-induced inﬂammation (tumor necrosis factor, monocyte chemoattractant protein
1, and chemokine [C-X-C motif] ligand 1) with prolonged therapeutic efﬁcacy as compared to NAC. Removal of complement
and/or Fc receptor binding did not affect h2G7 efﬁcacy. Conclusion: This is the ﬁrst report describing the generation of a partly
humanized HMGB1-neutralizing antibody with validated therapeutic efﬁcacy and with a prolonged therapeutic window, as com-
pared to NAC, in APAP-ALI. The therapeutic effect was mediated by HMGB1 neutralization and attenuation of postinjury
inﬂammation. These results represent important progress toward clinical implementation of HMGB1-speciﬁc therapy as a means
to treat APAP-ALI and other inﬂammatory conditions. (HEPATOLOGY 2016;64:1699-1710).
Drug-induced liver injury (DILI) is the leadingcause of acute liver injury (ALI), which isboth a clinical concern and results in drug
attrition, issuing of black box warnings, and drug with-
drawal from the market.(1) Acetaminophen (APAP) is
an analgesic and antipyretic and is generally safe when
taken at a therapeutic dose; however, intentional or
unintentional overdoses can lead to APAP-induced
acute liver injury (APAP-ALI) and represent around
50% of all cases of acute liver failure (ALF).(2,3)
Abbreviations: ALD, alcoholic liver disease; ALF, acute liver failure; ALI, acute liver injury; ALT, alanine aminotransferase; ANOVA, analysis of
variance; APAP, acetaminophen; APAP-ALI, acetaminophen-induced acute liver injury; CBA, cytometric bead array; CXCL, chemokine (C-X-C
motif) ligand; DILI, drug-induced liver injury; ELISA, enzyme-linked immunosorbent assay; endoS, endoglycosidase-S; FccR, Fcc receptors; GSH,
glutathione; HMGB1, high mobility group box 1; Ig, immunoglobulin; IP, intraperitoneal; I/R, ischemia-reperfusion; LCA, Lens culinaris agglutinin;
LT, liver transplantation; mAb, monoclonal antibody; MCP-1, monocyte chemoattractant protein 1; MD-2, myeloid differentiation protein 2; miR-
122, microRNA-122; NAC, N-acetylcysteine; NHS, normal human serum; PBS, phosphate-buffered saline; SDS-PAGE, sodium dodecyl sulfate poly-
acrylamide gel electrophoresis; SPR, surface plasmon resonance; TLR, Toll-like receptor; TNF, tumor necrosis factor.
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Clinical APAP intoxication is counteracted by peroral or
intravenous administration of N-acetylcysteine (NAC),
which has a narrow window for therapeutic intervention.
Untreated, APAP overdoses can lead to fulminant liver
failure, and the clinical outcome ranges from full recov-
ery, a need of liver transplantation (LT), or even death.
The post-APAP-associated inﬂammation (especially
innate immune activation), resulting from a substantial
hepatocellular necrosis, is associated with poor clinical
outcome (i.e., increased need for LT or death). For late
presenting patients, in whom inﬂammatory responses
are fulminant,(4) there are no effective treatment options
for severe cases of ALF beside LT. Because of the short-
age of potential liver donors and cost of LTs, there is an
urgent need for development of alternative therapeutic
strategies with broader therapeutic time windows than
NAC, including immunomodulatory drugs, in prevent-
ing APAP-ALI progression.
High mobility group box 1 (HMGB1) was discovered
16 years ago as an endogenous inﬂammatory mediator
and now serves as a prototype for the class of proinﬂam-
matory mediators denoted Alarmins. Alarmins are
released passively during cell death or from stressed cells.
During infectious and sterile inﬂammatory conditions,
HMGB1 is also actively released by immune cells,
enhancing and perpetuating inﬂammation and thus
contributing to the pathogenesis of a great number of
inﬂammatory diseases. The diverse inﬂammatory func-
tions of HMGB1 are mediated by multiple, different
reciprocal receptors. Global structural changes associated
with cysteine redox modiﬁcations of HMGB1 control its
receptor usage and thereby its bioactivities. HMGB1
induces cell migration in its fully reduced, all-thiol form
when interacting with chemokine (C-X-C motif) ligand
(CXCL)-12 and C-X-C chemokine receptor type 4,(5)
whereas cytokine production is induced by the disulﬁde
form interacting with the myeloid differentiation protein
2 (MD-2)/Toll-like receptor (TLR) 4 receptor com-
plex.(6,7) Furthermore, HMGB1 has also been demon-
strated to signal through receptor for advanced glycation
end products, TLR2, TLR9, CD24/Siglec, and T-cell
immunoglobulin and mucin-domain containing-3,(8)
with undetermined requirements for possible posttransla-
tional modiﬁcations. Additionally, active secretion of
HMGB1 is regulated by acetylation of HMGB1,(9) an
HMGB1-speciﬁc modiﬁcation that negatively correlates
with APAP-ALI patient outcome.(10)
HMGB1 plays a critical role in a wide array of
liver disease conditions, including liver ischemia-
reperfusion (I/R) injury, alcoholic liver disease (ALD),
cholestasis, and DILI. In liver I/R injury, necrotic cell
death is prominent and HMGB1 is released.(11) The
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pathogenic contribution of HMGB1 in hepatic I/R has
recently been shown through blockade of the interaction
between HMGB1 and MD-2.(7) Acetylated HMGB1
has been recorded in ALD patients and ethanol-fed
mice, demonstrating an inﬂammatory component and
active HMGB1 release in ALD. Furthermore, condi-
tional hepatocyte ablation of Hmgb1 is protective in a
mouse model of ethanol-induced liver injury.(12) Similar
HMGB1 isoforms have been recorded in obstructive
cholestasis patients,(13) supporting an active release and
inﬂammatory role of HMGB1 in this disease as well.
HMGB1 is required for post-APAP injury inﬂamma-
tion and has been shown to be pivotal in the progression
of APAP-ALI, and hepatocyte-speciﬁc HMGB1 deﬁ-
ciency improves survival.(14) In a clinical setting,
HMGB1 serves as a promising sensitive and speciﬁc
biomarker of APAP-ALI, outperforming alanine ami-
notransferase (ALT) as a marker of progression and as
an indicator of outcome.(2,10) The initial APAP-
induced hepatocyte necrosis results in an initial release
of all-thiol HMGB1. This leads to recruitment and
activation of immune cells, which propagate the inﬂam-
matory response, resulting in increased hepatocyte death
and exacerbation of injury.(14) HMGB1-speciﬁc anti-
body treatments have consolidated the pathogenic con-
tribution of HMGB1 in APAP-ALI, demonstrating
increased survival.(15)
Therapies targeting either the release of HMGB1,
interfering with HMGB1-receptor signaling or direct-
ly antagonizing HMGB1 (i.e., box A therapy), amelio-
rate disease severity and promote survival in a wide
spectrum of experimental disease models.(16) These
therapies are, however, unspeciﬁc in the sense that
they may affect other ligand-receptor interactions or
signaling pathways utilized by other molecules than
HMGB1. They may thus not be suitable for clinical
use. Importantly, targeting HMGB1 with the use of
antibodies speciﬁcally affects extracellular HMGB1
bioactivities, but will not interfere with its intracellular
functions. Successful HMGB1-speciﬁc polyclonal
antibody therapy was ﬁrst described in an acute inﬂam-
matory model of sepsis(17) and later in a chronic setting
of experimental arthritis models.(18) Polyclonal and
monoclonal antibody (mAb)-based therapies are pow-
erful tools in preclinical research. However, long-term
clinical success in humans with such antibodies is ham-
pered by the inherent immunogenicity of xenogeneic
antibodies that may cause safety issues and a negative
impact on clinical efﬁcacy.(19) The development of
humanized antibodies has signiﬁcantly reduced the
restricting xenogeneic immune responses. Chimeric
antibodies with the antigen-binding region kept xeno-
genic, targeting self-antigens are presently used suc-
cessfully to treat cancer (anti-CD20/rituximab), graft-
versus-host disease (anti-CD25/basiliximab), and vari-
ous autoimmune diseases (anti-TNF [tumor necrosis
factor]/inﬂiximab). The heterogeneity of diseases or
disorders with an inﬂammatory component empha-
sizes a continuous search for treatment reﬁnement and
creation of future therapies that speciﬁcally targets
novel pathogenic molecules.
To enable development of HMGB1-targeted thera-
py for clinical use, we set out to engineer a chimeric
anti-HMGB1 mAb (h2G7) by preserving the variable
regions of an extensively studied and effective mouse
mAb (m2G7) with recorded beneﬁcial anti-
inﬂammatory effects in multiple preclinical models
(Supporting Table S1). To verify well-maintained ben-
eﬁcial therapeutic effects, we utilized a highly
HMGB1-dependent experimental model of APAP-
ALI, which established that h2G7 provided equal
therapeutic beneﬁt as its murine analog. By modiﬁca-
tion of the CH2 domain, we could generate a variant
of h2G7 unable to activate the classical complement
pathway (K322A mutant) and an h2G7 variant inca-
pable of binding Fc-receptors (endoglycosidase-S
[endoS]-treated h2G7). By comparing the therapeutic
in vivo efﬁcacy of these three mAb variants, we con-
clude that h2G7 treatment alleviated APAP-ALI
through HMGB1 neutralization and has a prolonged
therapeutic window, as compared to NAC treatment.
Materials and Methods
A detailed description of experiments is described in
the Supporting Methods.
A chimeric anti-HMGB1 antibody (h2G7) with
human immunoglobulin (Ig) G1 isotype was generated
as described.(20,21) Brieﬂy, cDNA encoding the 2G7
mouse variable immunoglobulin domains was poly-
merase chain reaction ampliﬁed (Supporting Table S2)
and subcloned into plasmids encoding human constant
domains. Antibody speciﬁcity was tested by coating
plates with HMGB1, box A, or box B followed by
titration with increasing concentrations of mAbs.
Afﬁnities were analyzed by surface plasmon resonance
(SPR). Brieﬂy, mAbs were immobilized on a CM5-
dextran chip and recombinant HMGB1 was injected
at various concentrations (0, 55, 110, 220, and 880
nM). Determination of dissociation constants was per-
formed using Langmuir binding.
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Male C57BL/6J or CD-1 mice (Charles River,
Margate, UK) were fasted (15-16 hours) before intra-
peritoneal (IP) injection of APAP (530 or 300 mg/kg,
when indicated; Supporting Fig. S1). At 2 hours post-
APAP (or 6 hours, when indicated), 300 lg of anti-
HMGB1 antibodies, box A, E2 (irrelevant isotype
control), or 500 mg/kg of NAC were injected IP. At
10 hours post-APAP (or 24 hours, when indicated),
liver injury was determined by histology, serum ALT,
and expression of microRNA-122 (miR-122). Inﬂam-
matory mediators were analyzed by cytometric bead
array (CBA; BD Bioscience, Stockholm, Sweden).
Effector function-deﬁcient variants of h2G7, inca-
pable of binding complement or Fc receptors, were
generated by site-directed mutagenesis (K322A; Sup-
porting Table S2) or by endoS treatment. Inability to
activate complement was validated by a decrease in
C1q deposition from normal human serum (NHS).
Antibody deglycosylation was validated by a character-
istic mass-shift (sodium dodecyl sulfate polyacrylamide
gel electrophoresis [SDS-PAGE] analysis) and Lens
culinaris agglutinin (LCA) binding. Brieﬂy, antibodies
were coated onto plates followed by addition of
biotinylated LCA and subsequently visualized with
streptavidin/horseradish peroxidase and 3,30,5,50-tetra-
methylbenzidine. Fcc receptor (FccR) binding was
performed by binding of antibodies to human CD64-
coated plates or to live THP-1 cells. For binding to
THP-1 cells, h2G7 variant antibodies were incubated
with cells followed by detection with a ﬂuorescein
isothiocyanate-conjugated F(ab0)2 anti-human
antibody.
STATISTICAL ANALYSIS
Statistical analysis for in vivo studies was performed
with Kruskal-Wallis (Dunn’s posttest), and for in vitro
data, one-way analysis of variance (ANOVA) was per-
formed, where indicated. All statistical analysis was
performed using GraphPad Prism.
Results
CHARACTERIZATION
OF CHIMERIC 2G7 mAb
BIOACTIVITIES
We merged the variable domains of 2G7, obtained
from mouse (m2G7) hybridoma cells, with plasmids
encoding the human IgGc1 isotype and IgGj back-
bone in order to generate a chimeric anti-HMGB1
antibody (h2G7; Fig. 1A). The speciﬁc parent anti-
HMGB1 antibody (m2G7), that does not recognize
HMGB2, binds to the amino acids 53-63 within the
box A domain of rodent and human HMGB1.(22)
Given that antibody speciﬁcity may be inﬂuenced by a
change of IgG isotype,(23) we examined the antigen
speciﬁcity of h2G7 compared to m2G7. In similarity
to m2G7, h2G7 displayed dose-dependent binding to
full-length HMGB1 and the box A domain, but not
to the box B domain (Fig. 1B). By utilizing SPR, we
deﬁned the antibody binding afﬁnities for m2G7 (Kd
170 nM) and h2G7 (Kd 130 nM; Fig. 1C). This sug-
gests that h2G7 had a slightly higher afﬁnity toward
HMGB1 as compared to its murine counterpart,
although the recorded afﬁnities were within the same
order of magnitude. The human irrelevant IgG1 iso-
type control (E2)(20) did not bind to HMGB1, or the
box A or box B domains (Fig. 1B,C). Distinct func-
tional HMGB1 cysteine redox isoforms are present
during different phases of APAP-induced inﬂamma-
tion,(6,15) and it was previously unknown whether 2G7
selectively binds to any of these redox isoforms. We
therefore evaluated the binding capacity of m2G7 (Fig.
1D) and h2G7 (Fig. 1E) to all-thiol, disulﬁde, and sul-
phonyl HMGB1. Both m2G7 and h2G7 displayed
equal binding to all three isoforms tested, indicating
that 2G7 has the capacity to antagonize HMGB1 dur-
ing separate stages of inﬂammation.
EQUIVALENT THERAPEUTIC
EFFECTS OF h2G7 AND m2G7
The therapeutic in vivo effects of h2G7 were evalu-
ated in an experimental model of APAP-induced ALI
(Supporting Fig. S1). The pathogenic importance of
HMGB1 in this model has previously been established
by several reports.(2,7,15,24,25) Non-APAP-challenged
C57BL/6J mice were treated with phosphate-buffered
saline (PBS; vehicle), h2G7, m2G7, or the control E2
antibody. None of the treatments signiﬁcantly affected
hepatic glutathione (GSH) levels, as compared to the
PBS control, indicating that the treatments alone did
not affect hepatic APAP metabolite-scavenging ability
or APAP-bioconversion (Fig. 2A). No difference was
recorded between the treatment groups in non-APAP-
challenged mice with respect to serum ALT or miR-
122, a sensitive biomarker for hepatocyte damage (Fig.
2B,C). These results indicate that antibody treatments
were neither hepatotoxic nor did they alter baseline
levels of systemic liver injury markers.
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In mice challenged with APAP for 10 hours, hepat-
ic GSH concentrations dropped from 32.4 6 6.2 to
5.1 6 1.9 nmols/mg 6 SD (Fig. 2A). A comparable
GSH depletion was observed in all mice treated with
E2, m2G7, and h2G7 at 2 hours post-APAP, indicat-
ing similar APAP metabolism between treatment
groups (Fig. 2A). In concordance with previous studies
based on antibodies targeting HMGB1 in APAP-
challenged mice,(7,15) 2G7 treatments mediated a sig-
niﬁcant reduction in serum ALT and miR-122 levels
compared to the E2 control group (Fig. 2B,C). No
signiﬁcant difference was observed between the m2G7
and h2G7 treatment groups, indicating equivalent
hepatoprotective properties (Fig. 2B,C). APAP-
challenged mice showed characteristic hepatic patho-
physiological changes, as compared to normal mice
(Fig 2D and Supporting Fig. S2), and hepatic tissue
expression of HMGB1 was lost in central necrotic
areas, but up-regulated in periportal areas (Supporting
Fig. S2). Conﬁrmatory histological results revealed
reduced tissue destruction and alleviated inﬂammation
in h2G7-treated mice (Fig. 2D,E). A clear trend in
hepatoprotection, as analyzed by histology, was also
observed with m2G7 treatment, although this differ-
ence was not statistically signiﬁcant (Fig. 2E). Ki-67
stainings revealed that both m2G7 and h2G7 treat-
ment had signiﬁcantly less proliferating hepatocytes, as
compared to livers of E2-treated mice (Supporting
Fig. S3), suggesting a decrease in liver regeneration at
10 hours post-APAP. However, this may be explained
by the decrease in liver injury observed in m2G7- and
h2G7-treated mice (Fig. 2B-E).
Inﬂammatory mediators are up-regulated as a result
of the initial toxic hepatocellular injury induced by
APAP exposure.(26,27) Both PBS- and E2-treated mice
demonstrated a signiﬁcant increase in serum levels of
monocyte chemoattractant protein 1 (MCP-1), CXCL-
1, and TNF in APAP-exposed mice compared to non-
APAP-challenged animals (Fig. 2F). Anti-HMGB1
treatments signiﬁcantly reduced APAP-induced serum
levels of MCP-1 and completely abolished the serum
levels of CXCL-1 and TNF, as compared to the E2
treatment group. Both interleukin-1b and interferon-c
have been reported to be up-regulated post-APAP
administration(27); however, these cytokines were unde-
tectable in our experiments (data not shown).
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FIG. 1. Chimeric anti-HMGB1 antibody has retained speciﬁcity and afﬁnity as its murine analog. (A) Constant and variable domain
comparison of the parental mAb m2G7 and the chimeric h2G7 antibody denoted with known key residues regulating antibody effec-
tor functions. (B) Antigen speciﬁcity was tested by direct ELISA. HMGB1 (left), box A (middle), or box B (right) coated plates were
incubated with antibodies at increasing concentrations. h2G7 (green) and m2G7 (red) displayed similar antigen speciﬁcity by binding
to both HMGB1 and the box A domain, but not to box B. The control human IgG1 antibody E2 (black) did not display binding to
any of the proteins. (C) SPR analysis was performed to deﬁne binding afﬁnities to HMGB1. Antibodies were immobilized on a
CM5-dextran chip, and HMGB1 was injected at various concentrations (55, 100, 220, 440, or 88 0nM). h2G7 displayed slightly
higher afﬁnity (left, Kd 5 130 nM) toward HMGB1, as compared to m2G7 (middle, Kd 5 170 nM). No signal was detected from
the E2 channel (right). (D,E) Redox isoforms of HMGB1 were coated and (D) m2G7 or (E) h2G7 were added at increasing concen-
trations and detected with anti-mouse IgG or anti-human IgG, respectively. Abbreviations: OD, optical density; RU, response units.
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To evaluate the lowest effective therapeutic dose, we
administered one and two orders of magnitude less of
h2G7 antibody (i.e., 300, 30, or 3 lg/mouse). A dose-
dependent decrease in serum ALT and miR-122 (Fig.
3A,B) was observed. Interestingly, the lowest dose of
h2G7 (3 lg) did not signiﬁcantly decrease serum levels
of ALT or miR-122, but were still able to signiﬁcantly
block APAP-induced inﬂammation (Fig. 3C). This
supports that biomarker levels of hepatic injury is a
combined consequence of direct APAP-mediated tox-
icity and subsequent inﬂammation.
In order to explore whether the recorded hepatopro-
tection of 2G7 treatment was an effect observed exclu-
sively in inbred mice, we also investigated the
therapeutic effect of m2G7 treatment in an outbred
CD-1 mouse strain. In agreement with the results
observed in C57BL/6J mice, m2G7-treated CD-1 ani-
mals expressed signiﬁcantly reduced serum levels of
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FIG. 2. Similar therapeutic efﬁcacy of h2G7 and m2G7 following APAP-ALI. Fasted C57BL/6J mice were subjected to 530 mg/kg
of APAP. PBS, 300 lg of m2G7, h2G7, or IgG1 control antibody (E2) were administered at 2 hours post-APAP (n 5 6). At 10
hours post-APAP, (A) hepatic GSH, (B) serum ALT, (C) serum miR-122 expression, (D) representative histological sections (hema-
toxylin and eosin stainings), and (E) histological score were analyzed to evaluate hepatic injury. Levels of the inﬂammatory mediators
(F), TNF, CXCL-1, and MCP-1, in serum were quantiﬁed. If undetectable, values were substituted with the lowest limit of detection
(50 pg/mL). Data are presented as means 6 SEM. *P < 0.05 and **P < 0.01 by Kruskal-Wallis with Dunn’s posttest. Abbreviation:
Ct, threshold cycle.
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ALT, as compared to PBS-treated animals (Fig. 3D).
HMGB1-induced inﬂammatory effects are known to
be antagonized by the truncated box A domain of the
HMGB1 molecule, by means that are not fully resolved.
These therapeutic results have previously been demon-
strated in multiple experimental disease models,(18,28,29)
but never before studied in APAP-ALI. A single IP
injection of box A showed similar hepatoprotective
effects as the m2G7 treatment (Fig. 3D), conﬁrming
that other strategies for extracellular HMGB1 blockade
are also beneﬁcial in APAP-ALI. Injection of box A or
m2G7, in non-APAP-challenged CD-1 mice, did not
alter baseline hepatic GSH or serum ALT levels (Fig.
3D and Supporting Fig. S4). In line with these observa-
tions, a uniform decrease of hepatic GSH was observed
in all APAP challenged CD-1 mice regardless of treat-
ment (Supporting Fig. S4).
SPECIFIC ANTI-HMGB1 THERAPY
HAS A DELAYED THERAPEUTIC
WINDOW AS COMPARED TO NAC
Postinjury inﬂammation is highly deleterious in
APAP-ALI patients and is especially evident in late-
presenting patients where NAC treatment fails to con-
fer hepatoprotection. We therefore wanted to investi-
gate whether anti-HMGB1 treatment provided an
extended window of therapeutic intervention. APAP-
challenged mice (300 mg/kg) were treated with either
NAC, E2, or h2G7 at 2 or 6 hours post-APAP and
monitored for 24 hours. In line with previous reports,
NAC treatment at 2 hours post-APAP completely
abrogated the increase in serum ALT (Fig. 4A). How-
ever, NAC failed to confer hepatoprotection at 6 hours
post-APAP, whereas h2G7 treatment was hepatopro-
tective at both 2 and 6 hours post-APAP, as measured
by serum ALT levels (Fig. 4A,B). The reality in the
clinic is that most APAP-ALI patients receive NAC
treatment, and we thus, in addition, investigated the
effect of NAC-h2G7 combination treatment. We
could not record any beneﬁcial effects of the combina-
tion treatments at any time point (Fig. 4A,B), support-
ing that h2G7 treatment rather targets the postinjury
inﬂammation than the initial metabolic injury that is
counteracted by NAC treatment.
GENERATION OF EFFECTOR
FUNCTION-DEFICIENT h2G7
VARIANTS
Immunomodulatory effects of antibody therapies
can be mediated by several different mechanisms.
Antibodies may block the function of an antigen by
binding and neutralizing its target, by activating the
classical complement pathway through interaction
with C1q or by the engagement of FccRs and thus
inducing cell-mediated effects. In order to outline the
therapeutic importance of Fc-mediated effector func-
tions of h2G7 antibody in APAP-ALI, we generated
effector function-deﬁcient variants by modifying its
CH2 domain either by site-directed mutagenesis or by
endoS treatment, which removes N-linked glycosyla-
tion on the Fc part of antibodies.(30-32) Importantly,
none of the Fc-modiﬁed variants of h2G7 affected the
binding to HMGB1 (data not shown). A lysine-to-
alanine mutant variant of h2G7 was generated
(K322A), and in contrast to nonmodiﬁed h2G7, the
K322A variant completely abolished binding to human
C1q in vitro when coated directly (Fig. 5A) or when
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FIG. 3. Dose-dependent hepatoprotection and completely abolished
inﬂammation with anti-HMGB1 therapy. (A-C) APAP-challenged
C57BL/6J mice (530 mg/kg) were treated (2 hours post-APAP) with
h2G7 (3, 30, and 300 lg/mouse) or with 300 lg of E2 control anti-
body (n 5 6). Serum levels of (A) ALT and (B) miR-122 indicate a
dose-dependent hepatoprotection with h2G7 as treatment and a com-
plete abrogation of (C) inﬂammatory mediators, independent of thera-
peutic dose. If undetectable, values were substituted with the lowest
limit of detection (50 pg/mL). (D) Serum ALT levels in APAP-
challenged CD-1 mice (530 mg/kg) treated (2 hours post-APAP)
with PBS, 300 lg of m2G7, or 300 lg of box A for 10 hours (n 5 5
or 7). Results are presented as means6 SEM. *P < 0.05; **P < 0.01;
and ***P < 0.001 by Kruskal-Wallis with Dunn’s posttest. Abbrevia-
tions: Ct, threshold cycle; ns, not signiﬁcant.
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bound to plates coated with HMGB1 (Fig. 5B). In
similarity to the K322A mutant, endoS-treated h2G7
did not bind to C1q (data not shown).
Hydrolysis of the N-linked glycan at position N297
by endoS treatment was veriﬁed by a characteristic
mass shift (Fig. 6A) and by a reduced binding to LCA
(Fig. 6B and Supporting Fig. S5A), which speciﬁcally
binds to N-linked glycans. To verify that deglycosyla-
tion reduced FcR binding, we evaluated this binding
in vitro. Human IgG1 has the capacity to bind and
activate all members of the FccR family, and, as pre-
dicted, deglycosylation of h2G7 ablated binding to
human recombinant FccRI/CD64 (Fig. 6C and Sup-
porting Fig. S5B). We further investigated binding of
h2G7 to human THP-1 cells that express both CD64
and FccRII/CD16. The endoS treatment signiﬁcantly
reduced binding of h2G7 to THP-1 cells (Fig. 6D and
Supporting Fig. S5C). The K322A mutant and non-
modiﬁed h2G7 displayed similar binding to LCA,
CD64, and THP-1 cells (data not shown).
THERAPEUTIC PROPERTIES
OF EFFECTOR FUNCTION-
DEFICIENT h2G7
We next studied the therapeutic in vivo efﬁcacy of
the effector function-deﬁcient h2G7 variants in order
to elucidate the mechanism by which h2G7 elicits its
hepatoprotective and anti-inﬂammatory effect. Treat-
ment with the modiﬁed variant antibodies (K322A-
and endoS-treated h2G7) and h2G7 in APAP-
challenged mice showed similar hepatoprotective
effects, as determined by a comparable reduction of
serum ALT (Fig. 7A) and miR-122 (Supporting Fig.
S6). Equivalent anti-inﬂammatory effects, as measured
by reduced levels of TNF (Fig. 7B), CXCL-1 (Fig.
7C), and MCP-1 (Fig. 7D), were also recorded. These
results collectively establish that the therapeutic effects
of h2G7 were mediated by HMGB1 neutralization
rather than by complement activation or Fc receptor-
mediated effects.
Discussion
APAP is one of the most common over-the-counter
drugs and is generally safe at recommended therapeutic
doses. Nevertheless, APAP intoxication is a clinical
problem and may result in ALI or even death. During
clinical APAP overdose, a worse prognosis is correlat-
ed with activation of postinjury inﬂammation and sys-
temic inﬂammatory response syndrome.(2,4,27,33) Given
the inadequacy of current therapy (i.e., NAC), espe-
cially in late-presenting patients, there is a need for
development of novel therapies targeting the postinjury
inﬂammation. Speciﬁc immune-modulatory therapies
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FIG. 4. Targeting postinjury inﬂammation with h2G7 prolongs
the therapeutic window of opportunity compared to NAC treat-
ment. APAP-challenged C57BL/6J mice (300 mg/kg) were
treated (A) 2 or (B) 6 hours post-APAP with 300 lg of h2G7,
300 lg of E2 control antibody or 500 mg/kg of NAC alone or
in combination (n 5 10) and sacriﬁced at 24 hours post-APAP.
Hepatoprotection was recorded as a decrease in serum ALT lev-
els. Data are presented as means 6 SEM. *P < 0.05; **P <
0.01; and ***P < 0.001 by Kruskal-Wallis with Dunn’s posttest.
Abbreviations: ns, not signiﬁcant.
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FIG. 5. Abrogated binding to complement C1q in vitro by a
K322A mutation. Plates were coated with indicated antibodies
directly or with HMGB1. (A) Deposition of C1q from normal
human sera (NHS) on plates coated with K322A or h2G7.
Human serum albumin (HSA) or aggregated human IgG
(Agg.IgG) were used as negative and positive controls, respective-
ly. (B) K322A did not bind to C1q when complexed with
HMGB1. In experiments with HMGB1 coating, data were nor-
malized toward the h2G7 signal at 1% NHS, which was set as
100% C1q deposition. Results are represented as means 6 SEM
from three independent experiments. Abbreviation: OD, optical
density.
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are, as of yet, not available as treatment options for
APAP-ALI, although such therapeutic strategies
would potentially prolong the therapeutic window.
Indeed, our data strongly support that anti-HMGB1
therapy signiﬁcantly prolongs the therapeutic window
of experimental APAP-ALI (Fig. 4) and would likely
be invaluable in treatment of late-presenting patients
or in patients that do not respond satisfactorily to
NAC. HMGB1 has been shown to be a pivotal regula-
tor and biomarker of injury as a result of APAP over-
dose.(2,10) Therapeutic neutralization of HMGB1 has
the potential to improve outcome of several human
diseases, but no published clinical trials using
HMGB1-speciﬁc inhibitors have so far been con-
ducted. A paucity of HMGB1 antagonists suitable for
the clinic has, until now, been the major restricting ele-
ment for further progress. Accordingly, the main pur-
pose of this study was to engineer a chimeric
HMGB1-speciﬁc mAb with the potential to be evalu-
ated in future clinical trials, by investigating its
therapeutic efﬁcacy in a previously shown HMGB1-
dependent experimental model of APAP-ALI. We
believe that the outcome of our study, the partly
humanized h2G7, represents a promising candidate
for further clinical exploration.
Conserved proteins are poor immunogens, and rais-
ing protective therapeutic mAbs that target such pro-
teins is a challenging enterprise.(34) Hence, generating
therapeutically efﬁcient mAbs speciﬁc for HMGB1
(99% sequence conservation in mammalians) has prov-
en no exception to this experience. It took several years
after the original polyclonal anti-HMGB1 antibody
treatment study(17) until an anti-HMGB1 mAb
(m2G7) was demonstrated to confer experimental dis-
ease protection.(22,35) Although a few additional mouse
mAbs targeting HMGB1 have mediated successful
results in preclinical disease models,(36,37) none has
demonstrated comparable universal therapeutic efﬁcacy
as the 2G7 mAb that ameliorates diverse inﬂammatory
disease models (Supporting Table S1).
The generated chimeric 2G7 antibody, with its
replacement of the constant m2G7 frameworks with
human sequences, may possibly meet the drug devel-
opment requirements for an HMGB1 speciﬁc anti-
body therapy that would be suitable for clinical trials.
Humanization processes may alter both speciﬁcity and
afﬁnity of an antibody,(23) and for that reason, we
investigated whether a change in the constant Ig
framework modiﬁed the in vitro properties of 2G7.
Our results indicate that h2G7 did not interact with
anti-mouse IgG antibodies, implicating that removal
of the murine constant frameworks signiﬁcantly
reduced immunogenicity (data not shown), but with
preserved antigen speciﬁcity and afﬁnity (Fig. 1B,C).
The therapeutic efﬁcacy of m2G7 in preventing
HMGB1-induced sterile inﬂammation has emphasized
the clinical potential of 2G7 in several disorders (Sup-
porting Table S2) and especially in hepatic disor-
ders.(7,35) HMGB1 levels are increased in clinical and
experimental APAP-ALI and surpass ALT as a predic-
tor of clinical outcome post-APAP intoxication.(2,10)
The central functional role of HMGB1 in APAP-ALI
pathogenesis is highlighted by the fact that hepatocyte-
speciﬁc abrogation of Hmgb1 and anti-HMGB1 treat-
ment are highly protective in experimental models of
APAP-ALI.(7,14) In addition, extensive postinjury
inﬂammation negatively correlates with patient outcome
(i.e., need for LT or death). Our results, based on thera-
peutic interventions with h2G7 or m2G7, are in full
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FIG. 6. Aglycosylated h2G7 display reduced binding to Fc receptors
in vitro. Deglycosylation of h2G7 was performed by endoS treatment
and was analyzed by (A) reducing SDS-PAGE. A small decrease in
mass indicated deglycosylation of the IgGc chain. (B) LCA displayed
signiﬁcantly reduced binding to plates coated with endoS-treated
h2G7 as compared to nontreated h2G7. (C) EndoS treatment of
h2G7 signiﬁcantly reduced human recombinant CD64. (D) Binding
to live THP-1 cells incubated with PBS-, h2G7-, or endoS-treated
h2G7. Results are represented as means 6 SEM from three indepen-
dent experiments. ***P< 0.001 by one-way ANOVA with Bonferroni
posttest. Abbreviations: MFI, mean ﬂuorescence intensity; OD, opti-
cal density.
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agreement with this concept and conﬁrm retained func-
tionality of the novel h2G7 antibody. Furthermore,
therapeutic intervention with h2G7 is superior to NAC
treatment at late time points of experimental APAP-
ALI, possibly providing a novel treatment speciﬁcally
targeting postinjury inﬂammation with a prolonged
therapeutic window of opportunity at which NAC
treatment fails to confer hepatoprotection.
Recent structural HMGB1 studies emphasize that
the redox states of its three conserved cysteine residues
regulate the receptor-binding ability and subsequent
biological functions. Fully reduced HMGB1 (all-thiol)
acts a chemotactic factor, partially oxidized HMGB1
(disulﬁde) induces cytokines through TLR4/MD-2,
whereas the fully oxidized HMGB1 (sulfonyl) exerts
no demonstrable inﬂammatory activity.(6,38,39) All
three isoforms are systemically present in APAP-
challenged mice, although at different stages of postin-
jury inﬂammation.(6) HMGB1 isoforms (various redox
and acetylated isoforms) are readily detected by 2G7 in
immunoblotting analysis (data not shown) or by direct
enzyme-linked immunosorbent assay (ELISA; Fig
1D,E), but we cannot further comment on conceivable
binding preferences of the antibodies to any of the
HMGB1 isoforms in vivo. It has previously been dem-
onstrated that m2G7 inhibits both HMGB1-induced
cytokine production(39) as well as HMGB1-induced
cell migration in vitro (personal communication with
Prof. Marco E. Bianchi). Our in vivo-based studies
further support that h2G7 and m2G7 inhibits
HMGB1-driven cytokine and chemokine release in
experimental APAP-ALI equally well (Fig. 2F). Like-
wise, several in vivo models of sterile inﬂammation
have demonstrated that m2G7 suppresses both
HMGB1-induced migration and cytokine production
(Supporting Table S1). This collectively suggests that
2G7 hampers the effect of both known inﬂammatory
isoforms of HMGB1.
The hepatoprotective effects and elimination of
inﬂammatory mediators in response to 2G7 treatment
underline the pathogenic contribution of inﬂammation
in APAP-ALI, and that APAP-induced inﬂammation
is highly HMGB1 dependent. A single injection of 3
lg of h2G7 as well as the hepatoprotective dose of 300
lg completely eliminated the studied circulating
inﬂammatory mediators (Fig. 3). Yang et al. demon-
strated that treatment with low-dose m2G7 (5 lg) per
mouse at 2 hours and a repeated dose at 7 hours post-
APAP was both hepatoprotective and anti-
inﬂammatory at 24 hours post-APAP.(7) The higher
dose required in our study for hepatoprotection could
possibly be explained by experimental kinetic differ-
ences regarding the postinjury inﬂammatory response
or that a single low-dose injection of h2G7 is not sufﬁ-
cient to confer hepatoprotection. Nevertheless, the
functional similarities of h2G7 and m2G7 in the cur-
rent study suggest that h2G7 may exert life-saving
effects in APAP-induced ALI in a clinical setting.
None of the previous preclinical studies involving
m2G7 have addressed the mechanism of action of the
m2G7 parental antibody. The present generation of a
novel chimeric 2G7 antibody (h2G7) allowed us to, in
a controlled manner, modify its effector functions and
thus study its mechanism of action. In concurrence
with published data,(40) a K322A substitution of h2G7
completely suppressed C1q binding without affecting
binding to FccRs. The aglycosylated h2G7 was inca-
pable of binding neither C1q nor FccRs. Given that
deglycosylation of antibodies may affect binding to
C1q, it is important to recognize both isotype- and
species-speciﬁc differences, especially when conducting
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FIG. 7. Effector-function deﬁcient h2G7 variants demonstrate
analogous therapeutic effects as h2G7. APAP-exposed C57BL/6J
mice (530mg/kg) were treated with 300lg E2, K322A,
endoS-treated h2G7 or h2G7 at 2h post-APAP (n 5 6). (A)
K322A, endoS-treated h2G7 and h2G7 demonstrate equivalent
hepato-protective effects as measured by serum ALT. No signiﬁcant
difference was noted between the h2G7 treatment groups (gray bars)
with respect to anti-inﬂammatory activity as measured by a decrease
in (B) TNF, (C) CXCL-1, or (D) MCP-1. Undetectable levels
were substituted with the value for lowest limit of detection (50pg/
mL). Data are presented as means 6 SEM. **P < 0.01 and ***P <
0.001 by Kruskal-Wallis with Dunn’s posttest. Abbreviation: ns, not
signiﬁcant.
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studies comparing therapeutic antibodies.(31,32,41) The
binding of aglycosylated mouse IgG2b to C1q is negli-
gible and it is therefore likely that endoS-treated
m2G7 would have the same effect.(42) Our in vivo data
collectively suggest that h2G7 acts through antigen
neutralization, rather than complement activation or
FccR engagement, given that neither the K322A
mutant nor endoS-treated h2G7 displayed altered
therapeutic activity as compared to nonmodiﬁed
h2G7. The in vivo neutralizing effects of 2G7 could
possibly be explained by a direct steric blockade of
HMGB1-receptor interaction. As shown for other
therapeutic antibodies, it is conceivable that a competi-
tion for receptor binding sites is sufﬁcient for the
observed HMGB1 neutralization by h2G7 or that
allosteric mechanisms induce or suppress conforma-
tional changes, thus altering the function of
HMGB1.(43) Further in-depth studies are required to
deﬁne whether h2G7 has a preference for certain
HMGB1 isoforms and to elucidate the detailed mech-
anisms for h2G7-mediated neutralization.
To summarize, we here report the creation of a partly
humanized, chimeric mAb targeting HMGB1 with
preserved functionality compared to the parental mouse
anti-HMGB1 mAb. We conclude that HMGB1 neu-
tralization was the observed mechanism of action in
experimental APAP-ALI. The h2G7 antibody would
likely provide signiﬁcant advantages in a clinical setting
attributed to reduced xenogeneic immune responses and
improved pharmacokinetics, as compared to mouse
anti-HMGB1 mAbs, especially in late-presenting
patients and in patients with a need for repeated treat-
ment. These results provide distinct progress in the
endeavor to bring an HMGB1-speciﬁc antagonist to
further clinical development.
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